Cancer Gene Therapy Market Size & Share Report, 2024 – 2032

Cancer Gene Therapy Market – By Type (Ex-vivo, In-vivo), Therapy (Oncolytic Virotherapy, Gene-induced Immunotherapy, Gene Transfer), Product (Viral Vectors {Adenoviruses, Lentiviruses}, Non-viral Vectors), End-use, Global Forecast (2024 – 2032)

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600&nbsp;synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Rising R&amp;D investments and demand for novel cancer therapeutics

3.2.1.2&nbsp;&nbsp;&nbsp; Technological advancements in gene therapy

3.2.1.3&nbsp;&nbsp;&nbsp; Increasing incidence of cancer

3.2.1.4&nbsp;&nbsp;&nbsp; Increasing number of product approvals and launches

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High cost of therapy

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.6&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.4&nbsp;&nbsp;&nbsp; Strategic dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Type, 2021 &ndash; 2032 ($ Million)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Ex-vivo

5.3&nbsp;&nbsp;&nbsp; In-vivo

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Therapy, 2021 &ndash; 2032 ($ Million)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Oncolytic virotherapy

6.3&nbsp;&nbsp;&nbsp; Gene-induced immunotherapy

6.4&nbsp;&nbsp;&nbsp; Gene transfer

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product, 2021 &ndash; 2032 ($ Million)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Viral vectors

7.2.1&nbsp;&nbsp;&nbsp; Adenoviruses

7.2.2&nbsp;&nbsp;&nbsp; Lentiviruses

7.2.3&nbsp;&nbsp;&nbsp; Retrovirus

7.2.4&nbsp;&nbsp;&nbsp; Adeno associated virus

7.2.5&nbsp;&nbsp;&nbsp; Herpes simplex virus

7.2.6&nbsp;&nbsp;&nbsp; Vaccinia virus

7.2.7&nbsp;&nbsp;&nbsp; Other viral vectors

7.3&nbsp;&nbsp;&nbsp; Non-viral vectors

7.4&nbsp;&nbsp;&nbsp; Other products

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-use, 2021 &ndash; 2032 ($ Million)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Biopharma companies

8.3&nbsp;&nbsp;&nbsp; Research institutes

8.4&nbsp;&nbsp;&nbsp; Other end-users

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Million)

9.1&nbsp;&nbsp;&nbsp; Key trends, by region

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; Japan

9.4.2&nbsp;&nbsp;&nbsp; China

9.4.3&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Rest of the World

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Abeona Therapeutics Inc.

10.2&nbsp;&nbsp;&nbsp; Altor Bioscience Inc.

10.3&nbsp;&nbsp;&nbsp; Asklepios BioPharmaceutical Inc.

10.4&nbsp;&nbsp;&nbsp; Bluebird bio, Inc.

10.5&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company

10.6&nbsp;&nbsp;&nbsp; Elevate Bio

10.7&nbsp;&nbsp;&nbsp; Genelux Corporation

10.8&nbsp;&nbsp;&nbsp; GlaxoSmithKline Inc.

10.9&nbsp;&nbsp;&nbsp; Introgen Therapeutics Inc.

10.10&nbsp;&nbsp;&nbsp; Merck KGaA

10.11&nbsp;&nbsp;&nbsp; Novartis AG 
&nbsp;

Cancer Gene Therapy Market

Inquiry Before Buying